Monitoring Agency Report for the half year ended September 30, 2025
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has submitted its Monitoring Agency Report covering the first half of FY26 (April to September 2025). A Monitoring Agency Report is a routine regulatory filing required by companies that have raised money through public issues, rights issues, or preferential allotments, to track whether the funds are being used as originally disclosed. The report gives investors an update on how the capital raised from the market was deployed during this six-month period. Specific deployment details and any deviations from the stated purpose would be available in the full report attached to the filing.
This is a standard compliance disclosure with limited direct impact on the stock price. Shareholders should review the full report to check whether proceeds were used as promised, as any material deviation could be a red flag.